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Abstract
Background: Carbenoxolone (CBX) is a widely used gap junctional blocker. Considering several
reports indicating that transient gap junctional blockade could be a favourable intervention
following injuries to central nervous tissue, and some current enthusiasm in studies using systemic
injections of CBX, it is imperative to consider the penetration of CBX into central nervous tissue
after systemic administrations. So far, only very indirect evidence suggests that CBX penetrates
into the central nervous system after systemic administrations. We thus determined the amounts
of CBX present in the blood and the cerebrospinal fluid of rats after intraperitoneal administration,
using high performance liquid chromatography
Results: CBX was found in the blood of the animals, up to 90 minutes post-injection. However,
the cerebrospinal fluid concentration of CBX was negligible.
Conclusion: Thus, we conclude that, most likely, CBX does not penetrate the blood brain barrier
and therefore recommend careful consideration in the manner of administration, when a central
effect is desired.
Background
Carbenoxolone (CBX), a derivative of 18-glycyrrhetinic
acid [1], is a widely used drug which, in addition to being
a mineralocorticoid agonist and inhibiting 11-beta
hydroxysteroid dehydrogenase [2], also blocks gap junc-
tional communication [these issues nicely reviewed in ref-
erence [3]]. There has been an increasing enthusiasm in
the use of CBX in studies where gap junctional coupling
has to be altered, both in vitro [4-6] and in vivo [7-11].
Some of these in vivo studies attribute a possible effect of
CBX in the central nervous system (CNS) of the animals
[8,11] after systemic administration, thus assuming CBX
crosses the blood brain barrier. However, the only study
that suggested that CBX crosses the blood brain barrier is
the Jellinck et al. determination of the inhibition of 11-
beta-hydrysteroid dehydrogenase in brain after intraperi-
toneal (i.p.) injections [12].
To clarify this issue, we used a detection method based on
high performance liquid chromatography (HPLC) [13],
and assessed the drug concentration in blood and in cere-
brospinal fluid (CSF) samples of adult rats injected intra-
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peritoneally with CBX (50 mg/Kg). While CBX was found
in the plasma, its concentration in CSF was insignificant.
Results
Following an i.p. injection of CBX (50 mg/Kg), blood
samples were taken from the vein in the tail of the animal,
and CSF samples collected from the cisterna magna. A
total of 16 rats were used in this study. Figure 1 shows the
HPLC-determined CBX concentration in the blood sam-
ples, at several time points. We note that, in plasma sam-
ples, we obtained about 15–20% of the theoretically
estimated maximal CBX blood concentration (estimating
a blood volume of 10% of body weight), that is, assuming
all CBX was transferred to the circulation. However, one
hour and a half post-injection, the concentration in blood
had already dropped considerably to less than 200 µM.
The concentration of CBX in CSF was negligible (<1 µM)
at all time points tested, therefore we conclude that there
is no transfer from the circulation to the CSF. In previous
studies, we found that other compounds that are lipid sol-
uble can be detected by our HPLC system at similar levels
in plasma and in the CSF, such as acetone [14].
Discussion
There is a current considerable interest in the possible
roles of gap junctional communication in neuronal activ-
ity, and therefore a number of studies have used CBX as a
gap junctional blocker and have attributed a central action
of CBX after systemic administration. These studies
include CBX effects on epileptiform activity [8,15] or on
stereotypic behaviours [11]. Nevertheless, the only evi-
dence that indicated, albeit indirectly, that CBX penetrates
the blood brain barrier, was that presented in Jellinck et al.
[12]; however, this evidence is very indirect because the
studied relied on the CBX inhibition of 11-beta hydroxys-
teroid dehydrogenase, a relatively indirect measurement.
As well, brain tissue was homogenized for these studies,
which will include blood vessels and other tissues. A
clearer determination of CBX presence in tissue samples
can be obtained from specific fluid samples with the
HPLC method developed by Zhang [13].
That CBX was not found in CSF samples should not really
be surprising, as this molecule is polar and relatively large
[1,3], and therefore we can conceive that it will be difficult
to traverse the blood brain barrier. Hence, when looking
for a central effect of CBX, a direct, intracranial adminis-
tration will be more appropriate, using cannulae for
example [9]. However, our determination of CBX in CSF
samples still does not rule out completely the possibility
of a very transient crossing of the blood brain barrier by
the drug, if for instance, we envisage a situation in which
CBX is concentrated in brain tissue with little spill over
into the CSF. Because of the problems associated with
determining drug presence in brain tissue, which would
involve homogenisation of the tissue and thus bringing
along arteries and CSF vessels, we did not attempt these
analyses.
Considering current evidence that gap junctional blockers
may have a beneficial CNS effect after traumatic injuries
[5] or ischaemic insults [16,17], the issue of drug delivery
could become of importance for possible therapeutic
approaches. Hence, the creation of gap junctional ligands
that traverse the blood brain barrier could be an impor-
tant development. However, because of the breakdown of
the blood brain barrier that occurs after traumatic/ischae-
mic, epileptic, or inflammation injury, a penetration into
brain tissue can be expected in these conditions, consider-
ation to be taken into account for possible therapeutic
approaches.
Conclusion
Our results suggest that CBX does not penetrate the blood
brain barrier after i.p. administration, even though the
possibility of a transient residence into brain tissue cannot
be ruled out by these analyses. Hence, intracerebral injec-
tions are strongly recommended if the study is concerned
with possible brain effects of the drug. In addition, intrac-
erebral administration circumvents the potential con-
founding factor of systemic effects, which may be
mediated by mineralocorticoid receptor activation and
could contribute to the observed results.
Time course of CBX detected in the plasma after an i.p injec- tion of 50 mg/Kg Figure 1
Time course of CBX detected in the plasma after an i.p injec-
tion of 50 mg/Kg. Maximal plasma concentration (mean +/- 
SD) was found between 40-and 70 minutes post-injection.Publish with BioMed Central    and   every 
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Methods
Injections of CBX into animals and fluid withdrawal
CBX was purchased from Sigma. Male Long Evans rats
(50–60 days old) were injected intraperitoneally (i.p.)
with a dose of 50 mg/Kg. Blood (0.2 ml) was taken from
the rat's tail vein, and CSF samples (0.1 ml) were taken at
several time points after the drug injection, by puncturing
the cisterna magna using a syringe equipped with a 30 G
needle. Rats were anesthetized with halothane for all
these procedures. The experiments were approved by the
Hospital for Sick Children Animal care Committee
High Performance Liquid Chromatography (HPLC)
We used the Aiglent Hewlett Packard Model 1100 Series,
High performance liquid chromatography (HPLC) system
(Aiglent Technologies), equipped with a variable Wave-
length ultraviolet-visible detector. We followed the HPLC
method previously developed to determine carbenox-
olone concentration [13], using acetonitrile as compo-
nent A of the mobile phase, and potassium phosphate
buffer solution (pH 7.0) as component B. The mobile
phase had a flow rate of 1.0 ml/min with a proportion
12% to 88% for components A and B of the mobile phase,
respectively. Detection was performed with the UV detec-




HPLC: high performance liquid chromatography
i.p.: intraperitoneal
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